News & Events
Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
Crinetics will report first quarter 2026 financial results on Thursday, May 7, 2026 after the market closes. Company management will host a conference call at 4:30 pm ET to discuss financial results and provide a business update.
READ MOREWebcast: Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results
Event Date: May 7, 2026
READ MORECrinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly
Crinetics announces the submission of a Marketing Authorization Application (MAA) to Brazil’s National Health Surveillance Agency (ANVISA) for PALSONIFY™ (paltusotine), the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the proposed treatment of acromegaly in adults.
READ MORECrinetics to Participate in TD Cowen 46 Annual Health Care Conference
Event Date: March 4, 2026
READ MORECrinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Crinetics reports financial results for the fourth quarter and full year 2025. Company management will hold a live conference call and webcast on Thursday, February 26 at 4:30 PM ET.
READ MORECrinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
Crinetics announced that company management will participate in two upcoming investor conferences: the TD Cowen 46th Annual Health Care Conference in Boston, Massachusetts, and the Leerink Annual Global Healthcare Conference in Miami, Florida.
READ MORECrinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Crinetics announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes.
READ MORECrinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
Crinetics announced that the first patient has been dosed in the BALANCE-CAH Phase 2/3 trial evaluating investigational candidate atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate for the proposed treatment of classic congenital adrenal hyperplasia (CAH) in children and adolescents.
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
